Physician profile
Charles L Stimpson
NPI 1780654285
$1,486.63
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $648 · 2021: $276 · 2022: $39.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $203.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $197.98 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $140.30 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $136.58 | 2019-2020 | |
| Novo Nordisk INC | $118.52 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.25 | 2019-2021 | |
| Amarin Pharma, INC. | $114.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.53 | 2019-2020 | |
| Esperion Therapeutics, INC. | $70.34 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $57.34 | 2020 | |
| Abbvie INC. | $48.63 | 2021-2022 | |
| Glaxosmithkline, LLC. | $38.85 | 2020 | |
| Amgen INC. | $23.88 | 2021 | |
| Zyla Life Sciences, INC. | $23.74 | 2019 | |
| Pfizer INC. | $22.50 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.25 | 2019 | |
| Sanofi Pasteur INC. | $21.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.47 | 2019 | |
| Allergan, INC. | $11.73 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Stimpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.